The SUMOylation of TAB2 mediated by TRIM60 inhibits MAPK/NF-κB activation and the innate immune response.
The SUMOylation of TAB2 mediated by TRIM60 inhibits MAPK/NF-κB activation and the innate immune response.
复制标题
TRIM60 介导的 TAB2 SUMOylation 抑制 MAPK/NF-κB 激活和先天免疫反应
DOI:
10.1038/s41423-020-00564-w
复制
发表时间:
2021-08
影响因子:
24.1
通讯作者:
Hu H
中科院分区:
文献类型:
--
作者:
Gu Z;Chen X;Yang W;Qi Y;Yu H;Wang X;Gong Y;Chen Q;Zhong B;Dai L;Qi S;Zhang Z;Zhang H;Hu H
Activation of the TAK1 signalosome is crucial for mediating the innate immune response to pathogen invasion and is regulated by multiple layers of posttranslational modifications, including ubiquitination, SUMOylation, and phosphorylation; however, the underlying molecular mechanism is not fully understood. In this study, TRIM60 negatively regulated the formation and activation of the TAK1 signalosome. Deficiency of TRIM60 in macrophages led to enhanced MAPK and NF-κB activation, accompanied by elevated levels of proinflammatory cytokines but not IFN-I. Immunoprecipitation-mass spectrometry assays identified TAB2 as the target of TRIM60 for SUMOylation rather than ubiquitination, resulting in impaired formation of the TRAF6/TAB2/TAK1 complex and downstream MAPK and NF-κB pathways. The SUMOylation sites of TAB2 mediated by TRIM60 were identified as K329 and K562; substitution of these lysines with arginines abolished the SUMOylation of TAB2. In vivo experiments showed that TRIM60-deficient mice showed an elevated immune response to LPS-induced septic shock and L. monocytogenes infection. Our data reveal that SUMOylation of TAB2 mediated by TRIM60 is a novel mechanism for regulating the innate immune response, potentially paving the way for a new strategy to control antibacterial immune responses.
登录
查看更多内容
影响因子:
44.1
作者:
Hu H;Sun SC
通讯作者:
Sun SC
DOI:
10.1084/jem.20151426
发表时间:
2016-03-07
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Hu H;Wang H;Xiao Y;Jin J;Chang JH;Zou Q;Xie X;Cheng X;Sun SC
通讯作者:
Sun SC
DOI:
10.1084/jem.20161015
发表时间:
2017-04-03
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Hu MM;Liao CY;Yang Q;Xie XQ;Shu HB
通讯作者:
Shu HB
影响因子:
14.8
作者:
Bak RO;Dever DP;Porteus MH
通讯作者:
Porteus MH
影响因子:
29.7
作者:
Brubaker SW;Bonham KS;Zanoni I;Kagan JC
通讯作者:
Kagan JC